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Background: Hyperglycemia has been recognized as a primary factor in endothelial barrier dysfunction and in the
development of micro- and macrovascular diseases associated with diabetes, but the underlying biochemical
mechanisms remain elusive. Tyrosine phosphorylation of vascular endothelial cadherin (VE-cad) leads to the disruption
of endothelial adherens junctions and increases the transendothelial migration (TEM) of leukocytes.
Methods: VE-cad tyrosine phosphorylation, adherens junction integrity and TEM of monocytes in human umbilical vein
endothelial cells (HUVECs) treated with high-concentration glucose were evaluated. The role of protein kinase C (PKC)
in induction of endothelial cells adherence junction disruption by exposure of HUVECs to high concentration of glucose
was explored.
Results: The treatment of HUVEC with high-concentration glucose increased VE-cad tyrosine phosphorylation, whereas
mannitol or 3-O-methyl-D-glucose had no effect. In addition, high-concentration glucose increased the dissociation of
the VE-cad–β-catenin complex, activation of the Wnt/β-catenin pathway, and the TEM of monocytes. These alterations
were accompanied by the activation of endothelial PKC and increased phosphorylation of ERK and myosin light chain
(MLC). High-concentration glucose-induced tyrosine phosphorylation of VE-cad was attenuated by: 1- the inhibition of
PKC-β by overexpression of dominant-negative PKC-β 2- inhibition of MLC phosphorylation by overexpression of a
nonphosphorylatable dominant-negative form of MLC, 3- the inhibition of actin polymerization by cytochalasin
D and 4- the treatment of HUVECs with forskolin (an activator of adenylate cyclase).
Conclusions: Our findings show that the high-concentration glucose-induced disruption of endothelial adherens
junctions is mediated by tyrosine phosphorylation of VE-cad through PKC-β and MLC phosphorylation.
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Atherogenesis is a vascular inflammatory process charac-
terized by the enhanced recruitment of leukocytes to
dysfunctional endothelium [1]. An important early event
preceding the development of atheromatous lesions is
the infiltration of the arterial subendothelial intima by
macrophages/monocytes [2]. Interendothelial adherens* Correspondence: Mehran.Haidari@uth.tmc.edu
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unless otherwise stated.junctions (AJs) that maintain endothelial barrier function
are largely composed of vascular endothelial cadherin
(VE-cad), an endothelium-specific member of the cad-
herin family of adhesion proteins. Through its cytoplas-
mic domain, VE-cad binds to several proteins including
p120, β-catenin, and plakoglobin [3,4] that in turn bind
α-catenin, which links VE-cad to the actin cytoskeleton
[5]. Tyrosine phosphorylation of VE-cad disrupts endo-
thelial AJs by causing the dissociation of catenins from
VE-cad and thus facilitates the diapedesis of leukocytes
[6,7]. Myosin light chain (MLC) phosphorylation has a
critical role in increasing the permeability of endothelialLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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mediates the tyrosine phosphorylation of VE-cad in-
duced by the interaction of monocytes with endothelial
cells, leading to the enhanced transendothelial migration
(TEM) of monocytes [9]. Accelerated atherosclerosis is
the leading cause of morbidity and mortality in diabetic
patients [10]. Hyperglycemia has been implicated as an
underlying cause of cardiovascular, retinal, and renal
complications in diabetic patients; however, the mecha-
nisms are not known. Hyperglycemia increases the adhe-
sion of leukocytes to endothelial cells [11] possibly as
the result of the stimulatory effect of hyperglycemia on
the expression of adhesion molecules on the surface of
endothelial cells [12,13]. In addition, high glucose levels
increase the in vitro TEM of monocyte-like HL-60 cells
[14], although this effect has been attributed to an in-
crease in the phosphorylation of platelet-endothelial cell
adhesion molecule-1(PECAM-1). It has been demon-
strated that high concentration of glucose mediates an
increase in permeability of endothelial cells to albumin
by activation of protein kinase C [15]. However, the
integrity of AJs is a characteristic of endothelial barrier
that regulates TEM of monocytes [6,7] and might be inde-
pendent of permeability of endothelial cells to albumin.
The molecular mechanisms underlying the effect of high
concentration of glucose on integrity of endothelial
AJs and TEM of monocytes has not been fully ex-
plored. In our study, we hypothesized that high con-
centrations of glucose disintegrate endothelial AJs and
facilitate the TEM of monocytes through the protein
kinase C-mediated tyrosine phosphorylation of VE-cad.
Materials and methods
Reagents
Phospho-specific and nonphospho-specific antibodies
against Src (pY416), proline-rich tyrosine kinase-2 (Pyk2)
(pY402), glycogen synthase kinase 3-β (GSK3β, Ser 9),
β-catenin, ERK1/2, MYPT, GAPDH and cyclin D1
were purchased from Abcam. Phospho-specific and
nonphospho-specific antibodies against VE-cadherin
(Y731) and monoclonal 4G10 anti-phosphotyrosine Ab
were purchased from Invitrogen. Monoclonal phospho-
antibody against MLC and specific antibody against MLC
were purchased from Sigma-Aldrich. Mouse IgG was
purchased from Southern Biotech. Cytochalasin D, 3-
O-methyl-D-glucose, mannitol, D-glucose, phorbol myr-
istate acetate (PMA), forskolin, and protein kinase A
inhibitor H89 were purchased from Calbiochem. Premade
recombinant adenoviruses for dominant-negative (DN)-
protein kinase C (PKC)-α, null control, and green
fluorescent protein (GFP) and ViraDuctin adenovirus
transduction reagents were purchased from Cell Biolabs,
Inc. Premade recombinant adenoviruses for DN-PKC-β
and DN-PKC-δ were purchased from Applied BiologicalMaterials. The efficacy of all recombinant adenoviruses
was previously tested [9,16,17]. The luciferase reporters,
which contain either wild-type (TOPflash) or mutated
(FOPflash) binding sites for the lymphoid enhancer factor-
1/T-cell specific transcription factor (Lef-1/TCF) complex
were purchased from Millipore. The mutant construct for
MLC, in which Thr18 and Ser19 were replaced with ala-
nines (A-A-MLC) so that the protein could not be phos-
phorylated, was a generous gift from Dr. Andreas Kapus,
University of Toronto, Toronto, Canada, [18].
Cells
Human umbilical vein endothelial cells (HUVECs) and
human acute monocytic leukemia (THP-1) cells were
purchased from American Type Culture Collection. Hu-
man aortic endothelial cells (HAECs) were purchased
from Lonza. HUVECs and HAECs were grown in Lon-
za’s EGM-2-MV medium on collagen-coated (20 μg/ml)
tissue culture dishes. HUVECs and HAECs from fewer
than 4 generations were used for all experiments. THP-1
cells were maintained in Roswell Park Memorial Insti-
tute (RPMI) 1640 medium supplemented with 10% heat-
inactivated fetal calf serum (FCS). A single-donor human
peripheral blood buffy coat was purchased from the Gulf
Coast Regional Blood Center (Houston, TX, USA) and
used for isolation of peripheral blood monocytes.
Western blotting
HUVECs were grown to confluency in 35-mmol/l dishes
or 6-well plates. Cells were extracted in radioimmuno-
precipitation assay (RIPA) buffer, which contained 0.1%
SDS, 1% deoxycholate, 1% NP-40, 10 mmol/l sodium
phosphate, 150 mmol/l NaCl, 2 mmol/l EDTA, 50 mmol/l
NaF, 5 mmol/l sodium pyrophosphate, 0.1 mmol/l sodium
vanadate, 2 mmol/l PMSF, 0.1 mg/ml leupeptin, and 100
KIU/ml aprotinin. Samples were loaded onto an SDS-
PAGE gel and run at 150 V for 1 h. The proteins were
then transferred onto nitrocellulose paper at 300 mA for
1.5 h, followed by Western blot analysis. Blots were
blocked with 5% dry milk in 0.1% Tween 20 in PBS for 1 h
at room temperature. The primary antibodies were used
at a dilution of 1:500 to 1:1000. All antibodies were added
for 1 h at room temperature or overnight at 4°C. After
washing, the appropriate secondary antibodies (Pierce
Biotechnology, Inc., Rockford, IL, USA) were added at a
dilution of 1:10 000 for 1 h at room temperature. After
extensive washing, blots were developed with the Super
Signal enhanced chemiluminescence kit (Pierce) and
visualized on Kodak-AR film.
Immunoprecipitation
Cells were grown to confluency, washed gently with ice-
cold PBS twice, and lysed in 1 ml of RIPA lysis buffer.
After 10 min on ice, cell lysates were collected and
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After centrifugation (14 000 × g, 15 s at 4°C), the superna-
tants were incubated with primary antibodies (1 μg/mg
lysate) overnight at 4°C with continuous mixing. Protein
A-agarose (40 μl) was added to the lysate. After 2 h at 4°C,
the beads were washed 3 times in lysis buffer, and proteins
were eluted by boiling in SDS-sample buffer containing
4% 2-mercaptoethanol (Bio-Rad, Hercules, CA, USA). The
samples were analyzed by SDS-PAGE.
Transduction of adenovirus
The conditions used for the transduction of recombinant
adenoviruses were optimized by using adenovirus encod-
ing GFP. All reagents and kits, including transduction
reagents, an adenovirus purification kit, and an adeno-
virus titration kit, were purchased from Cell Biolabs, Inc.
After purification, the titration of each recombinant
adenovirus was determined by an ELISA titrating kit.
HUVECs were seeded into 6-well plates for 24 h until
they reached 80% confluence. According to the manu-
facturers’ protocol, adenovirus was transduced into cells
by using ViraDuctin (Cell Biolabs, Inc.). HUVECs were
infected with adenoviral vectors with a multiplicity of
infection (MOI) of 100 plaque-forming units per cell in
the presence of ViraDuctin. After incubation with viral
particles for 48 h, the cells were assessed for the expres-
sion of the transduced genes.
Transfection of plasmids
The vector pcDNA3.1/CT-GFP TOPO (Invitrogen) was
used to optimize the transfection of plasmids into HUVECs.
Plasmids were transfected into cells by using Lipofectamine
2000 (Invitrogen). Empty pcDNA3.1 vector was transfected
as controls. Cells were collected 48 h after transfection
with plasmids.
Immunofluorescence studies
Cells were grown in wells of 4-chamber culture collagen-
coated slides. Cells were fixed in 4% paraformaldehyde for
15 min at 4°C, washed with PBS, and permeabilized for
5 min with 0.1% Triton-X-100. After blocking with
PBS + 2% BSA + 0.1% Tween-20, cells were incubated
with primary antibody against β-catenin and goat anti-
rabbit IgG for 45 min each. Images were acquired by
MicroSuite FIVE software (Olympus Soft Imaging Solu-
tions, Golden, CO, USA) with an Olympus BX61 motorized
microscope (Olympus America, Center Valley, PA, USA).
TEM assay
A kit from Cell Biolabs, Inc. was used for TEM assays
according to the manufacturer’s instructions. THP-1
cells (25 × 106 each) were resuspended in 1 ml of complete
medium and incubated for 1 h at 37°C in the presence of
50 μg/ml calcein-AM (Molecular Probes, Invitrogen).After the cells were labeled, they were resuspended at a
concentration of 1 × 106 cell/ml in DMEM. The lower
chamber was filled with assay medium plus 10 ng/ml of
monocyte chemotactic protein (MCP)-1. THP-1 cells
(1.5 × 105 in 150 μl) were added to the upper compart-
ment of transwell chambers with 6.5-mm diameter and
5-μm pores for 2 h. The cells that spontaneously detached
from the undersurface of the filter were removed by the
swab and were quantified with an Ultra384 plate reader
(Tecan) by using 485 and 535 nm excitation and emission
filters, respectively.
Luciferase reporter assay
Briefly, HUVECs (1.5 × 104) were seeded in a 12-well
plate and were transiently transfected with 0.3 μg of
TOPflash or FOPflash along with 10 ng of pRL-SV40
(Promega) by using Lipofectamine 2000 (Invitrogen).
After 48 h, the cells were treated with glucose (12.5, 25,
or 50 mM, 24 h), PMA (50 nM, 8 h), LiCl (10 mM, 8 h).
Cells were then lysed, and luciferase activity was deter-
mined by using a Dual-Luciferase® Reporter Assay Sys-
tem (Promega). The luciferase activity of each sample
was normalized with that of Renilla, used for monitoring
transfection efficiency.
PKC total activity
PKC activity was measured by using a MESACUP pro-
tein kinase assay kit (MBL International), which is based
on an enzyme-linked immunosorbent assay, according
to the manufacturer’s protocol. Briefly, subconfluent
HUVECs were washed 3 times with cold phosphate-
buffered saline (PBS), scraped with a rubber policeman,
and suspended in 1 mL of cold sample preparation buf-
fer (50 mM Tris–HCl [pH 7.5], 5 mM EDTA, 10 mM
EGTA, 50 mM 2-mercaptoethanol, 1 mM PMSF, 10 mM
benzamidine). The phosphatidylserine (PS) peptide plate
was phosphorylated by incubation with 30 μg/mL cell
lysate, 3 mM MgCl2, 2 mM CaCl2, 0.1 mM ATP, 50 μg/mL
phosphatidylserine, 0.5 mM EDTA, 1 mM EGTA, 5 mM
2-mercaptoethanol, and 25 mM Tris–HCl (pH 7.0) at
25°C for 10 min. The biotinylated monoclonal antibody
2B9 was used to bind the phospho-PS peptide and was
subsequently detected with peroxidase-conjugated strep-
tavidin. A peroxidase substrate was then added to the
microwells, and color intensity was measured spectro-
photometrically at 492 nm.
Statistics
Transmigration data were analyzed by analysis of vari-
ance (ANOVA), and a 2-sample Student t test was used
to calculate statistical significance (Excel, Microsoft
Corp., Houston, TX, USA). All experiments were re-
peated at least 3 times. A probability (P) value <0.05
was considered significant.
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Treatment of Endothelial Cells with High-Concentration
Glucose Leads to the Disintegration of Endothelial AJs
The treatment of HUVECs with high concentrations of
D-glucose, otherwise referred to as glucose, for 24 hours
increased tyrosine phosphorylation of VE-cad in a dose-
dependent manner (Figure 1A). In addition, phosphoryl-
ation of the tyrosine kinases Src and Pyk2 that regulate
the tyrosine phosphorylation of VE-cad was also in-
creased in HUVECs treated with high concentrations of
glucose (Figure 1A). To confirm tyrosine phosphoryl-
ation of VE-cadherin after treatment of HUVECs with
high glucose VE-cadherin was immunoprecipitated and
then tyrosine phosphorylation was tested with monoclonal
4G10 anti-phosphotyrosine Ab. As indicated in Figure 1B
tyrosine residues of VE-cadherin was phosphorylated after
treatment of HUVECs with high concentration of glucose.Figure 1 Treatment of endothelial cells with high-concentration gluco
phosphorylation of VE-cad (PY731), Src (PY416), and Pyk2 (PY402) was indu
with glucose for 24 h using phosphospecific antibodies. B, Treatment of HUVE
of VE-cadherin, VE-caherin was immunoprecipitated and then blotted with 4G
glucose for 24 h led to the dissociation of β-catenin from VE-cad. VE-cad a
antibodies were used for the detection of each respective protein. mIgG (mou
Treatment of HUVECs with the indicated concentrations of glucose for 24 h inc
human peripheral blood monocytes. TEM of THP-1 cells (D) and primary huma
assay. Calcein-labeled THP-1 cells/ primary human peripheral blood monocytes
as the mean ± SD from triplicate experiments. F, G, Treatment of HUVECs with
24 h did not significantly affect the tyrosine phosphorylation of VE-cad. H
concentrations of glucose for 24 h led to tyrosine phosphorylation of VE-
was independently performed 3 to 4 times.When HUVECs were treated with 25 mM glucose, the
VE-cad–β-catenin complex was dissociated (Figure 1C).
In addition, the TEM of THP-1 cells (a monocytic
leukemia cell line) was significantly increased in a
dose-dependent manner in HUVECs treated with high
concentrations of glucose (Figure 1D). Similar studies
with primary human peripheral blood monocytes
showed comparable results, indicating that these findings
are not specific to THP-1 cells (Figure 1E). In contrast to
high-concentration glucose, neither mannitol nor 3-O-
methyl-D glucose (a nonmetabolizable glucose analogue)
altered VE-cad tyrosine phosphorylation in HUVECs after
24 hours (Figure 1F and G). Similar to HUVECs treated
with high concentrations of glucose, human aortic endo-
thelial cells (HAECs) treated with high concentrations of
glucose for 24 h also showed a dose-dependent increase
in VE-cad tyrosine phosphorylation (Figure 1H). Thesese leads to the disintegration of adherens junctions. A, Tyrosine
ced in human umbilical vein endothelial cells (HUVECs) after treatment
Cs with high concentration of glucose leads to tyrosin phosphorylation
10 anti phospho-tyrosine antibody. C, Treatment of HUVECs with 20 mM
ntibody was used for immunoprecipitation, and β-catenin and VE-cad
se non-immune IgG) was used as an immunoprecipitation control. D, E,
reased the transendothelial migration (TEM) of THP-1 cells and primary
n peripheral blood monocytes (E) were evaluated by using a transwell
were quantified by using a fluorescence plate reader. Data are expressed
the indicated concentrations of mannitol and 3-O-methyl-D glucose for
, Treatment of human aortic endothelial cells with the indicated
cad. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control. Each experiment
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the integrity of endothelial AJs, which is associated by an
increase in the tyrosine phosphorylation of VE-cad.
High-Concentration Glucose–Induced VE-cad Tyrosine
Phosphorylation Is Mediated by PKC-β
Activation of PKC contributes to microvascular barrier
dysfunction [19] and inhibition of PKC-β reverses car-
diac microvascular barrier dysfunction in diabetic rats
[20]. We recently demonstrated that the treatment of
HUVECs with the PKC activator PMA increases the
tyrosine phosphorylation of VE-cad, the dissociation of
β-catenin from the VE-cad complex, and the TEM of
invasive breast cancer cells, MDA-MB-231 cells [21].
Therefore, we hypothesized that PKC plays a role in the
high-concentration glucose–induced disruption of endo-
thelial AJs. We found that the treatment of HUVECs with
high-concentrations of glucose led to a dose-dependent
increase in the activation of endothelial PKC (Figure 2)
and the phosphorylation of ERK (Figure 2B), which leadsFigure 2 Protein kinase C (PKC) plays a role in the high-concentration
A, Treatment of human umbilical vein endothelial cells (HUVECs) with gluc
was measured spectrophotometrically at 492 nm by using a colorimetric en
three independent experiments were performed. B, Treatment of HUVECs
of HUVECs with 10 μM PKC inhibitor, bisindolylmaleimide I (Bis), for 2 h att
of VE-cad. HUVECs were first treated with 20 mM of glucose for 24 h. D, Tr
respectively. Total PKC activity was measured spectrophotometrically at 492
technique. E, Treatment of HUVECs with 50 nM of phorbol myristate ace
transendothelial migration (TEM) of THP-1 cells. HUVECs were washed w
THP-1 cells were evaluated by using a transwell assay. Calcein-labeled TH
are expressed as the mean ± SD from triplicate experiments. *P < 0.05, **P
performed 3 to 4 times.to MLC phosphorylation and VE-cad tyrosine phosphoryl-
ation [9]. In addition, high-concentration glucose–induced
tyrosine phosphorylation of VE-cad was attenuated
when HUVECs were treated with bisindolylmaleimide,
an inhibitor of PKC (Figure 2C). Treatment of HUVECs
with 50 nM PMA for 48 h resulted in a significant
reduction in PKC activity (Figure 2D). Furthermore,
when HUVECs were depleted of PKC by lengthy treat-
ment with PMA (48 h), the high-concentration glucose–
induced TEM of THP-1 cells was reduced (Figure 2E).
In addition, the inhibition of intracellular calcium by
BAPTA-AM (N',N'-tetraacetic acid) attenuated the high-
concentration glucose-induced tyrosine phosphoryl-
ation of VE-cad (Figure 3A), suggesting a role for
conventional PKC (ie, PKC-α, −β1, −β2, and -γ) in the
high-concentration glucose-induced tyrosine phosphor-
ylation of VE-cad. Similar experiments with HAECs
demonstrated that PKC mediates high glucose-induced
tyrosine phosphorylation of VE-cad (data not shown).
When PKC-β, PKC-α, or PKC-δ was inhibited byglucose-induced disruption of endothelial adherens junctions.
ose for 24 h led to an increase in total PKC activity. Total PKC activity
zyme-linked immunosorbent assay technique. For each sample shown,
with glucose for 24 h increased ERK1/2 phosphorylation. C, Treatment
enuated high-concentration glucose-induced tyrosine phosphorylation
eatment of HUVECs for 1 and 48 h increased and inhibited PKC activity,
nm by using a colorimetric enzyme-linked immunosorbent assay
tate (PMA) for 48 h attenuated high-concentration glucose-induced
ith the cell culture medium before addition of THP cells. The TEM of
P-1 cells were quantified by using a fluorescent plate reader. Data
< 0.01, ***P < 0.001 vs. control. Each experiment was independently
Figure 3 High-concentration glucose-induced tyrosine phosphorylation of VE-cad is mediated by protein kinase C (PKC)-b. A, Treatment
of human umbilical vein endothelial cells (HUVECs) with 10 μM of cell-permeant intracellular calcium chelator, BAPTA-AM, for 2 h attenuated
high-concentration glucose-induced tyrosine phosphorylation of VE-cad. HUVECs were first treated with 20 mM of glucose for 24 h. B, Overexpression of
recombinant dominant-negative (DN)-PKC-β but not DN-PKC-α or DN-PKC-δ attenuated high-concentration glucose-induced tyrosine phosphorylation of
VE-cad. C, Overexpression of DN-PKC-β but not DN-PKC-α or DN-PKC-δ reduced basal-level tyrosine phosphorylation of VE-cad. D, Overexpression
of recombinant dominant-negative (DN)-PKC-β but not DN-PKC-α or DN-PKC-δ attenuated high-concentration glucose-induced dissociation of
β-catenin from VE-cadherin complex. VE-cad antibody was used for immunoprecipitation, and β-catenin and VE-cad antibodies were used for
the detection of each respective protein. mIgG (mouse non-immune IgG) was used as an immunoprecipitation control. *P < 0.05, **P < 0.01,
***P < 0.001 vs. control. Each experiment was independently performed 3 to 4 times.
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protein, only PKC- β abolished high-concentration
glucose–induced VE-cad tyrosine phosphorylation
(Figure 3B). We also found that the inhibition of PKC-β
but not the inhibition of PKC-α or PKC-δ by overex-
pression of the corresponding dominant-negative protein
inhibited basal levels of VE-cad tyrosine phosphorylation
by 25% (Figure 3C). Inhibition of PKC-β but not of
PKC-α or PKC-δ by over expression of the correspond-
ing dominant-negative protein resulted in suppression
of high glucose induced dissociation of β-catenin from
VE-cadherin complex (Figure 3D). These results suggest
that high-concentration glucose-induced VE-cad tyro-
sine phosphorylation is mediated by PKC-β.
Phosphorylation of MLC Mediates Tyrosine Phosphorylation
of VE-cad Induced by High-Concentration Glucose
Because MLC phosphorylation plays a crucial role in
VE-cad tyrosine phosphorylation induced by the inter-
action of monocytes with endothelial cells [9] we studied
the role of MLC phosphorylation and actin polymerization
in the high-concentration glucose-induced tyrosinephosphorylation of VE-cad. The high-concentration
glucose-induced tyrosine phosphorylation of VE-cad
was accompanied by an increase in the phosphorylation
of MLC and the regulatory subunit of MLC phosphatase
(MYPT, Figure 4A). Phosphorylation of MYPT inhibits
MLC phosphatase [22]. A nonphosphorylatable mutant
construct for MLC in which Thr18 and Ser19 are re-
placed with alanines (AA-MLC) was used to study the role
of MLC phosphorylation in high-concentration glucose-
induced tyrosine phosphorylation of VE-cad [9,17]. The
inhibition of MLC phosphorylation by the overexpression
of DN-AA-MLC (GFP transfection rate, 40%; Figure 4B)
and the inhibition of actin polymerization by cytochalasin
D (1 μM, 2 h; Figure 4C) attenuated the high-concentration
glucose-induced tyrosine phosphorylation of VE-cad,
suggesting a crucial role for MLC phosphorylation in
mediating the effects of high-concentration glucose on the
tyrosine phosphorylation of VE-cad. Studies with HAECs
indicated that induction of VE-cad tyrosine phosphoryl-
ation by high glucose is mediated by MLC phosphoryl-
ation (data not shown). Given that PKA inhibits MLC
phosphorylation [23] we examined the effects of PKA
Figure 4 Phosphorylation of myosin light chain (MLC) mediates high-concentration glucose-induced tyrosine phosphorylation of
VE-cad. A, Treatment of human umbilical vein endothelial cells (HUVECs) with glucose for 24 h led to phosphorylation of MLC and MLC
phosphatase regulatory subunit (MYPT). B, High-concentration glucose-induced VE-cad tyrosine phosphorylation was attenuated in HUVECs
overexpressing mutant MLC (AA-MLC), in which Thr18 and Ser19 are replaced with alanines. HUVECs were transfected with the indicated constructs
and, after 48 h, were treated with 20 mM glucose for 24 h. C, Cytochalasin D suppressed high-concentration glucose-induced tyrosine phosphorylation
of VE-cad. HUVECs were treated with 20 mM glucose for 24 h and then 1 μM cytochalasin D for 2 h. D, Treatment of HUVECs with protein kinase A
inhibitor H89 for 2 h led to tyrosine phosphorylation of VE-cad. E, Treatment of HUVECs with 10 μM forskolin for 2 h (an activator of adenylate cyclase)
attenuated high-concentration-induced tyrosine phosphorylation of VE-cad. HUVECs were first treated with 20 mM of glucose for 24 h. *P < 0.05,
***P < 0.001 vs. control. Each experiment was independently performed 3 to 4 times.
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VE-cad tyrosine phosphorylation in HUVECs in a dose-
dependent manner (Figure 4D). Furthermore, because the
cAMP/PKA signaling pathway stabilizes the barrier prop-
erty of endothelial cells [24,25] we examined the effect
of increasing the concentration of cAMP on the high-
concentration glucose-induced tyrosine phosphoryl-
ation of VE-cad. In HUVECs treated with forskolin
(an activator of adenylate cyclase), the high-concentration
glucose-induced tyrosine phosphorylation of VE-cad was
attenuated (Figure 5E). These results suggest that the
high-concentration glucose-induced tyrosine phosphor-
ylation of VE-cad is mediated by MLC phosphorylation.High-Concentration Glucose Induces Phosphorylation of
GSK3β and Transactivation of β-catenin–Responsive
Genes
Dissociation of AJs leads to the internalization of cadherin-
bound β-catenin and its accumulation in the perinuclear
endocytic recycling compartment [26]. Upon stimula-
tion of the wingless (Wnt) signaling pathway, glycogen
synthase kinase-3β (GSK3β), a protein that is part of the
complex that regulates the proteasomal degradation of
β-catenin, is inactivated/phosphorylated, and β-catenin
is translocated to the nucleus where it associates with
Lef-1/TCF to activate target gene transcription and bio-
logical responses [27,28].
Figure 5 High-concentration glucose induces the phosphorylation of GSKβ (Ser9) and the intracellular accumulation of b-catenin. A, B,
Treatment of human umbilical vein endothelial cells (HUVECs) with glucose (10–30 mM, 24 h), LiCl (10 mM, 4 h), or PMA (12.5-50 nM, 4 h) increased
phosphorylation of GSK3β (Ser 9). C, Treatment of HUVECs with 50 nM of PMA for 48 h attenuated high-concentration-glucose-induced
GSK3β phosphorylation. After treatment of the indicated samples with PMA for 48 h, glucose was added to the indicated samples for 24 h
before GSK3β (Ser 9) phosphorylation was evaluated. D, Treatment of HUVECs with 20 mM of glucose for 24 h or 50 nM of PMA for 4 h induced
the translocation of β-catenin into the cytoplasm and nuleus of the cells. HUVECs were fixed with 4% paraformaldehyde and stained with primary
rabbit polyclonal antibody against β-catenin and secondary FITC-conjugated goat anti-rabbit IgG antibody (green). Hoechst was used to
stain the nuclei (blue). Bar = 10 μm. Magnification, 63X. ***P < 0.001, **P < 0.01, and *P < 0.05 vs. control. Each experiment was independently
performed 3 to 4 times.
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after high-concentration glucose-induced dissociation of
β-catenin from VE-cad, we studied the phosphorylation
of GSK3β and the cellular localization of β-catenin. The
treatment of HUVECs with high concentrations of glucose
(24 h) or PMA (4 h) resulted in the dose-dependent inac-
tivation/phosphorylation of GSK3β (Figure 5A and B).
GSK3β was also phosphorylated when HUVECs were
treated with LiCl, a known inhibitor of GSK3β (Figure 5A).
When HUVECs were depleted of PKC by lengthy treat-
ment (48 h) with PMA, the high-concentration glucose-
induced phosphorylation of GSK3β was significantly
reduced (Figure 5C), suggesting that PKC mediates high-
concentration glucose-induced GSK3β phosphorylation.
The treatment of HUVECs with high-concentration
glucose or PMA (4 h) resulted in the accumulation of
intracellular β-catenin (Figure 5D).
To determine whether high-concentration glucose in-
duces the transactivation of β-catenin-responsive genes,
we performed luciferase reporter assays using luciferase
reporters that contain either the wild-type (TOPflash)
or mutated (FOPflash) binding sites for the Lef-1/TCF
complex, which have been widely used to characterize
β-catenin-TCF-dependent gene expression [29]. High-concentration glucose, PMA, or LiCl significantly increased
TOPflash Lef-1/TCF-responsive promoter activity but
had no effect on FOPflash promoter activity (Figure 6A).
Furthermore, the treatment of HUVECs with high-
concentration glucose, PMA, or LiCl increased the protein
expression of cyclin D1, which is encoded by a β-catenin–
responsive gene (Figure 6B and C). In addition, the mRNA
expression of another β-catenin–responsive gene, uro-
kinase plasminogen activator, u-PA but not the endothe-
lial cell marker CD31, was also increased after HUVECs
were treated with high-concentration glucose, PMA, or
LiCl (Figure 6D). These results suggest that the Wnt/β-
catenin pathway is activated in endothelial cells treated
with high concentrations of glucose.
Discussion
In our study, we showed that the treatment of endo-
thelial cells with high-concentration glucose led to the
tyrosine phosphorylation of VE-cad, the dissociation of
β-catenin from the VE-cad complex, and the increased
TEM of monocytes. Furthermore, the disruption of
endothelial AJ integrity induced by high-concentration
glucose was mediated by PKC-β-dependent MLC phos-
phorylation and was associated with the activation of the
Figure 6 High-concentration glucose induces the transactivation of β-catenin-responsive genes. A, Glucose (10–30 mM, 24 h), PMA (50
nM, 8 h), and LiCl (10 mM, 8 h) induced an increase in TOPflash but not mutant FOPflash luciferase activity in human umbilical vein endothelial
cells (HUVECs). Three independent experiments were performed. Luciferase activity was normalized to that of Renilla and is expressed as a percentage
of the control. B, C, Western blot analysis showing that the treatment of HUVECs with glucose (24 h), LiCl (10 mM, 16 h) or PMA (16 h) increased
protein expression of cyclin D1. D, Real-time PCR analysis showing that the treatment of HUVECs with glucose (10–30 mM, 24 h), LiCl (10 mM, 8 h), or
PMA (50 nM, 8 h) increased mRNA expression of urokinase plasminogen activator, u-PA but not the endothelial cell marker CD31. Expression
levels for the u-PA gene were normalized to those of the housekeeping gene β2-microglobulin. Data are expressed as the mean ± SD of 4
independent experiments. ***P < 0.001; **P < 0.01, and *P < 0.05 vs. control. Each experiment was independently performed 3 to 4 times.
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vide evidence of a mechanism that may underlie the
increased risk of atherosclerosis in patients with diabetes.
Recent studies in low-density lipoprotein receptor–
deficient mice, which are hyperglycemic but exhibit no
marked dyslipidemia when compared with nondiabetic
controls, showed that diabetes in the absence of diabetes-
induced hyperlipidemia is associated with the accelerated
formation of atherosclerotic lesions, similar to what is seen
in fat-fed nondiabetic mice [30]. The observed increase in
the adhesion of leukocytes to endothelial cells has been
attributed to the hyperglycemia-induced overexpression of
endothelial adhesion molecules [31]. Our studies suggest
that the high-concentration glucose–induced disruption
of endothelial AJs may also be a mechanism underlying
accelerated atherosclerosis in diabetes. Based on the
results of our previous studies [9,16,17,32] we have
developed a hypothetical model [9] for how the inter-
action of monocytes with endothelial cells leads to the
enhancement of monocyte TEM. We showed that in-
creased phosphorylation of MLC by inhibition of MLC
phosphatase leads to tyrosine phosphorylation of VE-cad
[9]. Several signaling pathways regulate MLC phos-
phorylation, including PKC, Rho-family GTPases, andRAS [32-37]. Therefore, we logically speculated that
the same pathways regulate VE-cad tyrosine phosphor-
ylation. Our previous and current findings support this
hypothesis [9,16,17]. However, further investigation is
needed to identify the underlying mechanisms by
which high-glucose-induced phosphorylation of MLC
leads to VE-cad tyrosine phosphorylation. It is possible
that MLC phosphorylation and actomyosin contraction
trigger not only mechanical and cytoskeletal changes in
endothelial cells but also lead to the redistribution of
kinases and phosphatases that regulate VE-cad tyrosine
phosphorylation. Such a mechanism may contribute to
the phosphorylation of VE-cad in endothelial cells treated
with high-concentration glucose. Previous studies showed
that actin polymerization, RhoA activity, and myosin activ-
ity are required for the recruitment and accumulation of
junctional complex components [38,39]. Two nonreceptor
tyrosine kinases that regulate the tyrosine phosphorylation
of VE-cad-Src and Pyk2 [9] -associate with VE-cad [40,41].
We showed that the interaction of monocytes with endo-
thelial cells or the overexpression of constitutively active
HRas in endothelial cells recruits Src to the VE-cad com-
plex [9]. In this study, we showed that the treatment of
HUVECs with high-concentration glucose resulted in the
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the accumulation of intracellular β-catenin, an increase in
TCF-responsive promoter (TOPflash) activity, and the
transactivation of the β-catenin–responsive genes cyclin
D1 and u-PA. It has been shown that u-PA and its cell sur-
face receptor, u-PAR, are overexpressed in atherosclerotic
plaques and may contribute to vascular wall inflammation
[42]. In addition, in vivo microscopy analysis of the
cremaster muscle in mice showed that endothelial u-PA
promotes the TEM of neutrophils [43]. Vascular endo-
thelial growth factor (VEGF), which is known to in-
crease VE-cad tyrosine phosphorylation [44], induces
the hyperpermeability of endothelial cells by activating
the u-PA/u-PAR system through the transcriptional ac-
tivation of β-catenin, thus increasing u-PAR expression
[45]. Moreover, u-PA increases the permeability of endo-
thelial cells [46]. Interestingly, u-PA activates ERK in many
different cell types including endothelial cells [47,48].
Furthermore, uPA promotes cellular migration by initi-
ating a u-PAR–dependent signaling cascade in which
Ras, MEK, ERK, and MLC kinase serve as essential
downstream effectors [49].
These findings suggest that u-PA may initiate the signal
transduction that leads to VE-cad tyrosine phosphorylation
and the disruption of AJs. Additional studies are needed to
determine the role of high-concentration glucose-induced
u-PA expression in endothelial AJ integrity.
Conclusions
We showed that treatment of endothelial cells with high-
concentration glucose leads to the PKC-β–mediated
disruption of endothelial AJs and the activation of the
Wnt/β-catenin signaling pathway. The results of this study
provide supportive in vitro evidence for a possible
molecular mechanism underlying the increased risk
of atherosclerosis in diabetes.
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